Relationship between proinsulin-to-insulin ratio and advanced glycation endproducts in Japanese type 2 diabetic subjects

Diabetes Research and Clinical Practice

Volumn 78, Issue 2, 2007, Pages 182-188

  Saisho, Yoshifumi ^a,b   Maruyama, Taro ^b   Hirose, Hiroshi ^a   Saruta, Takao ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Saitama Social Insurance Hospital   (Japan)

Author keywords

Advanced glycation endproducts; Oxidative stress marker; Proinsulin; Proinsulin to insulin ratio; Type 2 diabetes

Indexed keywords

8 ISOPROSTANE; ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID PEROXIDE; PENTOSIDINE; PROINSULIN;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; INSULIN BLOOD LEVEL; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HOMEOSTASIS; HUMANS; INSULIN; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROINSULIN;

EID: 34648814400     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.03.014     Document Type: Article

References (34)

1. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
2. Duckworth W.C., Kitabachi A.E., and Heinemann M. Direct measurement of plasma proinsulin in normal and diabetic subjects. Am. J. Med. 53 (1972) 418-427
3. Mako M.E., Starr J.I., and Rubenstei A.H. Circulating proinsulin in patients with maturity onset diabetes. Am. J. Med. 63 (1977) 865-869
4. Yoshioka N., Kuzuya T., Matsuda A., Taniguchi M., and Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31 (1988) 355-360
5. Gordon P., Hendricks C.M., and Roth J. Circulating proinsulin-like component in men: increased proportion in hypoinsulinemic states. Diabetologia 10 (1974) 469-474
6. Kahn S.E., Leonetti D.L., Prigeon R.L., Boyko E.J., Bergstrom R.W., and Fujimoto W.Y. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 44 (1995) 173-179
7. Nijpels G., Popp-Snijders C., Kostense P.J., Bouter L.M., and Heine R.J. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia 39 (1996) 113-118
8. Haffner S.M., Gonzalez C., Mykkänen L., and Stern M. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 40 (1997) 830-837
9. Inoue I., Takahashi K., Katayama S., Harada Y., Negishi K., Ishii J., et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabet. Med. 13 (1996) 330-336
10. Mykkänen L., Haffner S.M., Hales C.N., Ronnemaa T., and Laakso M. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 46 (1997) 1990-1995
11. Røder M.E., Porte Jr. D., Schwartz R.S., and Kahn S.E. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 83 (1998) 604-608
12. Mykkänen L., Zaccaro D.J., Hales C.N., Festa A., and Haffner S.M. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia 42 (1999) 1060-1066
13. Pfützner A., Kunt T., Hohberg C., Mondok A., Pahler S., Konrad T., et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabet. Care 27 (2004) 682-687
14. Ohyama Y., Utsugi T., Uchiyama T., Hanaoka T., Hasegawa A., Tomono S., et al. The elevated proinsulin-to-insulin ratio is associated with oxidative stress in Down's syndrome. Diabetologia 44 (2001) 788-789
15. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46 (1995) 223-234
16. Kajimoto Y., and Kaneto H. Role of oxidative stress in pancreatic β-cell dysfunction. Ann. N.Y. Acad. Sci. 1011 (2004) 168-176
17. Yamamoto Y., Hirose H., Saito I., Nishikai K., and Saruta T. Adiponectin an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J. Clin. Endocrinol. Metab. 89 (2004) 87-90
18. Pfützner A., Kunt T., Langenfeld M., Lobig M., Knesovic M., and Forst T. Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin. Clin. Chem. Lab. Med. 41 (2003) 1234-1238
19. Ono Y., Aoki S., Ohnishi K., Yasuda T., Kawano K., and Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabet. Res. Clin. Pract. 41 (1998) 131-137
20. Sanaka T., Funaki T., Tanaka T., Hoshi S., Niwayama J., Taitoh T., et al. Plasma pentosidine levels measured by newly developed method using ELISA in patients with chronic renal failure. Nephron 91 (2001) 64-73
21. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabet. Care 27 (2004) 1487-1495
22. Rhodes C.J., and Alarcon C. What β-cell defect could lead to hyperproinsulimemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 43 (1994) 511-517
23. Inoguchi T., Umeda F., Kakimoto M., Sako Y., Ishii H., Noda K., et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr. J. 47 (2000) 763-770
24. Kumakura S., Iwamoto Y., Kuzuya T., Shiraishi I., Matsuda A., and Saito T. Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment. Diabet. Res. Clin. Pract. 29 (1995) 107-112
25. Prigeon R.L., Jacobson R.K., Porte D., and Kahn S.E. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81 (1996) 3295-3298
26. Rachman J., Levy J.C., Barrow B.A., Manley S.E., and Turner R.C. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Diabetes 46 (1997) 1557-1562
27. Ammari F., Davies M.J., Koppiker N., Gregory R., and Burden A.C. The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with type 2 diabetes mellitus. Diabet. Med. 16 (1999) 142-146
28. Muller G., Satoh Y., and Geisen K. Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabet. Res. Clin. Pract. Suppl. (1995) S115-S137
29. Nagi D.K., Ali V.M., and Yudkin J.S. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet. Med. 13 (1996) 753-757
30. Ovalle F., and Bell D.S. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes. Diabet. Care 27 (2004) 2585-2589
31. Smith S.A., Porter L.E., Biswas N., and Freed M.I. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin: insulin ratio in type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 6048-6053
32. Tiedge M., Lortz S., Drinkgern J., and Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46 (1997) 1733-1742
33. Kaneto H., Fujii J., Myint T., Miyazawa N., Islam K.N., Kawasaki Y., et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic β-cells by provoking oxidative stress through the glycation reaction. Biochem. J. 320 (1996) 855-863
34. Tajiri Y., Möller C., and Grill V. Long term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology 138 (1997) 273-280